Regulatory Daily Summary
Regulatory Daily Summary: What Happened on November 1, 2026
FDA proposes one-application framework for individualized gene editing
Draft guidance covers product variation and postapproval oversight for treatments targeting rare genetic diseases.
Today in brief
The FDA's proposed review framework could allow developers to make some product changes within a single biologics license application for individualized genome-editing treatments.1 Public comments are open through November 27.1
Draft guidance would set bounds for product changes
The FDA issued draft guidance on October 27 covering applications and postapproval oversight for individualized genome-editing products targeting rare genetic diseases.1 It proposes an “Individualized Feature Space” to define permissible product variation within one biologics license application, potentially allowing changes within those bounds without additional trials.1
The agency is accepting public comments through November 27.1